Preferred Label : Septooptic dysplasia;
CISMeF acronym : CPHD5;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : De morsier syndrome;
Included titles and symbols : Pituitary hormone deficiency, combined, 5; Growth hormone deficiency with pituitary anomalies; CPHD5;
Description : Septooptic dysplasia is a clinically heterogeneous disorder loosely defined by any
combination of optic nerve hypoplasia, pituitary gland hypoplasia, and midline abnormalities
of the brain, including absence of the corpus callosum and septum pellucidum (Dattani
et al., 1998). The diagnosis of this rare congenital anomaly is made when 2 or more
features of the classic triad are present. Approximately 30% of patients have complete
manifestations, 62% display hypopituitarism, and 60% have an absent septum pellucidum.
The disorder is equally prevalent in males and females and is more common in infants
born to younger mothers, with a reported incidence of 1 in 10,000 live births (summary
by Webb and Dattani, 2010). Also see 516020.0012 for a form of septooptic dysplasia
associated with cardiomyopathy and exercise intolerance.;
Inheritance : Autosomal dominant; Autosomal recessive;
Molecular basis : Caused by mutation in the homeo box gene expressed in ES cells (HESX1, 601802.0001);
Laboratory abnormalities : Low or absent growth hormone (GH); Low or absent adrenocorticotropic hormone (ACTH); Low or absent follicle-stimulating hormone (FSH); Low or absent thyrotropin (TSH); Low or absent luteinizing hormone (LH);
Prefixed ID : #182230;
Origin ID : 182230;
UMLS CUI : C0338503;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)